- Home
- JELD vs FHTX Comparison
JELD vs FHTX Comparison
Compare JELD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JELD
- FHTX
- Stock Information
- Founded
- JELD 1960
- FHTX 2015
- Country
- JELD United States
- FHTX United States
- Employees
- JELD N/A
- FHTX N/A
- Industry
- JELD Forest Products
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- JELD Basic Materials
- FHTX Health Care
- Exchange
- JELD Nasdaq
- FHTX Nasdaq
- Market Cap
- JELD 221.3M
- FHTX 246.6M
- IPO Year
- JELD 2017
- FHTX 2020
- Fundamental
- Price
- JELD $1.81
- FHTX $5.00
- Analyst Decision
- JELD Hold
- FHTX Strong Buy
- Analyst Count
- JELD 7
- FHTX 6
- Target Price
- JELD $4.61
- FHTX $11.83
- AVG Volume (30 Days)
- JELD 1.9M
- FHTX 270.9K
- Earning Date
- JELD 11-03-2025
- FHTX 11-05-2025
- Dividend Yield
- JELD N/A
- FHTX N/A
- EPS Growth
- JELD N/A
- FHTX N/A
- EPS
- JELD N/A
- FHTX N/A
- Revenue
- JELD $3,304,951,000.00
- FHTX $24,518,000.00
- Revenue This Year
- JELD N/A
- FHTX $42.43
- Revenue Next Year
- JELD $2.44
- FHTX $14.77
- P/E Ratio
- JELD N/A
- FHTX N/A
- Revenue Growth
- JELD N/A
- FHTX N/A
- 52 Week Low
- JELD $1.82
- FHTX $2.95
- 52 Week High
- JELD $11.66
- FHTX $8.45
- Technical
- Relative Strength Index (RSI)
- JELD 11.86
- FHTX 65.31
- Support Level
- JELD $2.12
- FHTX $4.63
- Resistance Level
- JELD $2.65
- FHTX $5.69
- Average True Range (ATR)
- JELD 0.24
- FHTX 0.40
- MACD
- JELD -0.10
- FHTX 0.13
- Stochastic Oscillator
- JELD 0.57
- FHTX 80.12
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.